Steroid-refractory acute graft versus host disease
Clinical trials for Steroid-refractory acute graft versus host disease explained in plain language.
Never miss a new study
Get alerted when new Steroid-refractory acute graft versus host disease trials appear
Sign up with your email to follow new studies for Steroid-refractory acute graft versus host disease, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for chinese patients with severe transplant complication: ruxolitinib trial launches
Disease control OngoingThis study tests the drug ruxolitinib in 36 Chinese adults and teens (12+) who have severe graft-versus-host disease after a stem cell transplant and did not improve with steroids. Participants take ruxolitinib pills daily for up to 56 days. The main goal is to see how many patie…
Matched conditions: STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cell therapy aims to tame deadly transplant complication in kids
Disease control OngoingThis study tests a new treatment called MC0518 (made from donor cells) in children who have severe graft-versus-host disease (GvHD) after a stem cell transplant and did not get better with steroids. GvHD happens when the donor's immune cells attack the child's body. The trial com…
Matched conditions: STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE
Phase 2 • Sponsor: medac GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC